The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Eur Respir Rev. 2024 Feb 14;33(171). doi: 10.1183/16000617.0145-2023. Print 2024 Jan 31.
Lung cancer is the leading cause of cancer-related deaths worldwide, and ∼85% of lung cancers are classified as nonsmall cell lung cancer (NSCLC). These malignancies can proliferate indefinitely, in part due to dysregulation of the cell cycle and the resulting abnormal cell growth. The specific activation of cyclin-dependent kinases 4 and 6 (CDK4/6) is closely linked to tumour proliferation. Approximately 80% of human tumours exhibit abnormalities in the cyclin D-CDK4/6-INK4-RB pathway. Specifically, CDK4/6 inhibitors either as monotherapy or combination therapy have been investigated in pre-clinical and clinical studies for the treatment of NSCLC, and promising results have been achieved. This review article focuses on research regarding the use of CDK4/6 inhibitors in NSCLC, including the characteristics and mechanisms of action of approved drugs and progress of pre-clinical and clinical research.
肺癌是全球癌症相关死亡的主要原因，约 85%的肺癌被归类为非小细胞肺癌 (NSCLC)。这些恶性肿瘤可以无限期增殖，部分原因是细胞周期失调和由此导致的异常细胞生长。细胞周期蛋白依赖性激酶 4 和 6 (CDK4/6) 的特异性激活与肿瘤增殖密切相关。大约 80%的人类肿瘤表现出细胞周期蛋白 D-CDK4/6-INK4-RB 通路的异常。具体来说，CDK4/6 抑制剂无论是单独使用还是联合治疗，都已经在 NSCLC 的临床前和临床研究中进行了研究，并取得了有希望的结果。这篇综述文章重点介绍了 CDK4/6 抑制剂在 NSCLC 中的应用研究，包括已批准药物的特征和作用机制以及临床前和临床研究的进展。
